Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 10 SULFITE FREE W ELECT IN DEXTROSE 10 W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLINIMIX E 5/10 provides essential amino acids, electrolytes, and dextrose for parenteral nutrition, supporting protein synthesis and energy metabolism. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis. Electrolytes maintain acid-base balance and osmotic regulation.
Travasol 4.25% in Dextrose 20% is a parenteral nutrition solution providing amino acids and carbohydrates. Amino acids serve as substrates for protein synthesis, while dextrose supplies calories to prevent catabolism and promote anabolism. The solution corrects nitrogen balance and provides energy.
Intravenous infusion. Dosage is individualized based on patient's metabolic requirements, clinical condition, and laboratory parameters. Typical adult dose: 1.5-2 g amino acids/kg/day and 10-15 g dextrose/kg/day (max 5 mg/kg/min dextrose). Rate: Infuse via central line at ≤ 3 mL/kg/hr initially, titrate up to 100-125 mL/hr. Do not exceed 125 mL/hr.
Intravenous administration via central line. Typical adult dose: 500-1000 mL/day of TRAVASOL 4.25% in dextrose 20% (providing 4.25 g amino acids and 20 g dextrose per 100 mL) as part of total parenteral nutrition. Infusion rate: not to exceed 0.8 g/kg/h of amino acids. Individualize based on metabolic needs.
None Documented
None Documented
Amino acids: variable, ~1-2 hours for most, reflecting rapid metabolism and utilization. Dextrose: not applicable as endogenous molecule; infusion half-life ~15-30 minutes due to insulin-mediated clearance. Clinical context: renal impairment prolongs amino acid elimination.
Not applicable; components are endogenous nutrients. Dextrose half-life <15 min in normal renal function; amino acids have variable half-lives (minutes) due to rapid metabolism and incorporation. Clinical context: continuous infusion maintains steady state.
Amino acids and electrolytes are primarily excreted renally. Dextrose is metabolized to CO2 and water, exhaled via lungs. Unmetabolized dextrose excreted renally if threshold exceeded. Less than 5% biliary/fecal.
Renal excretion; amino acids are reabsorbed or metabolized, excess nitrogen excreted as urea (renal). Dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution